IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play?
This article compares two healthcare-focused ETFs: the iShares U.S. Healthcare ETF (IYH) and the First Trust NYSE Arca Biotechnology Index Fund (FBT). IYH offers broad exposure to the healthcare sector with 100 holdings and a lower expense ratio, while FBT is a more concentrated play on biotechnology with 30 stocks and higher volatility. Although FBT has shown higher recent returns, IYH is more cost-efficient and has a lower maximum drawdown.
Y Intercept Hong Kong Ltd Acquires Shares of 1,055,367 Kenvue Inc. $KVUE
Y Intercept Hong Kong Ltd has acquired over 1 million shares of Kenvue Inc. (NYSE:KVUE) worth approximately $20.2 million, making it their 29th largest position. This acquisition comes as Kenvue slightly missed its Q2 earnings expectations, though revenue still grew 3% year-over-year. Analysts currently hold a "Hold" rating on the stock with a consensus price target of $19.27, and Kenvue offers a quarterly dividend yielding about 4.4%.
This Insider Has Just Sold Shares In Ecolab
Ecolab's Co-Chief Operating Officer, Gregory Russell Cook, recently sold US$1.3 million worth of company stock, reducing his holding by 23%. Despite this sale, insider transactions over the last year show more buying than selling, with insiders purchasing US$2.9 million worth of shares compared to US$1.3 million in sales. Insiders hold 0.1% of Ecolab shares, valued at approximately US$92 million, indicating a reasonable alignment with shareholder interests.
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
Taiho Pharmaceutical and Cullinan Therapeutics announced that their EGFR inhibitor, zipalertinib, met its primary endpoint of progression-free survival in a Phase 3 trial for first-line non-small cell lung cancer with EGFR exon 20 insertion mutations. This success positions them to compete with Johnson & Johnson's Rybrevant in this niche market. Cullinan stands to gain $100 million upon first-line approval, in addition to $30 million for a pending second-line approval.
BNP Paribas Exane cuts Alcon stock rating on competitive pressure
BNP Paribas Exane downgraded Alcon Inc. to Neutral from Outperform, citing competitive pressures in its intraocular lens business and difficult comparisons in the Instruments segment. The firm also lowered its price target, anticipating that new products won't significantly improve growth until early to mid-2027. Despite a recent earnings beat driven by one-time items, Alcon's Implantables segment faces headwinds from competitors like Johnson & Johnson, leading to downside risk for future earnings growth projections.
How ABBV Stock Moved Away From Its Peer Group
AbbVie (ABBV) has shown strong fundamental performance with high revenue growth and operating margins, yet its stock returns significantly lag behind peers like Merck and Johnson & Johnson. This disconnect is attributed to the market pricing in future competitive threats to AbbVie's key drug franchises, despite management's efforts to build new growth platforms, particularly in its neuroscience division with an upcoming Parkinson's drug. Investors are looking to the success of these new ventures to determine if the stock price will eventually reflect the company's strong operational metrics.
Decoy Therapeutics (DCOY) posts wider Q2 loss, flags going-concern and Nasdaq risks
Decoy Therapeutics (DCOY) reported a wider net loss of $2.37 million in Q2 2026, compared to $957,825 a year earlier, and a six-month net loss of $4.59 million. The biotechnology company disclosed substantial doubt about its ability to continue as a going concern, projecting its current cash will only fund operations into late 2026. Furthermore, Decoy highlighted potential delisting risks due to a proposed Nasdaq rule requiring a $5 million minimum market value of listed securities, given its current market capitalization.
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
The article compares Johnson & Johnson (J&J) and AbbVie as investment options, focusing on their dividend characteristics and business strategies. J&J offers a safer, more diversified dividend with a 64-year streak and an AAA-rated balance sheet, while AbbVie provides a higher yield but carries more single-product risk, despite its aggressive M&A strategy and strong immunology franchise. The author recommends J&J for income investors seeking safety and AbbVie for those pursuing total return with a higher risk tolerance.
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
This article compares Johnson & Johnson (JNJ) and AbbVie (ABBV) for dividend investors, highlighting J&J's safer, diversified portfolio and 64-year dividend streak against AbbVie's higher yield but greater concentration in immunology. While J&J offers a secure dividend with a AAA-rated balance sheet, AbbVie's recent acquisition and focus on post-Humira growth via drugs like Skyrizi present a higher-risk, potentially higher-reward scenario for total return. The author leans towards J&J for income and AbbVie for total return, based on their differing risk profiles and growth strategies.
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales
Eli Lilly has filed six lawsuits against U.S. companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The lawsuits target compounding pharmacies, medical spas, and online sellers, as retatrutide is still in Phase 3 clinical trials and not yet approved by the FDA. This action is part of Lilly's broader effort to combat the black market for weight-loss drugs, which has seen a surge in demand and increased interception by U.S. Customs and Border Protection.
Albany International Corporatio (AIN) Stock Forecasts
Argus has lowered its target price for Albany International Corp (AIN) to $50.00, while the current stock price is $63.84. Albany International Corp is primarily involved in processing textiles and materials. The report was published on August 5, 2026.
Legend Biotech stock downgraded at Oppenheimer (LEGN:NASDAQ)
Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform following the resignation of its CEO, competitive pressures, and reduced M&A prospects. The analyst cited these factors as reasons for the downgrade. Legend Biotech's shares saw a decline on Wednesday after the announcement.
J&J, Thinkbaby, Honest Co. Veterans Join Nice Advisory Team
The Nice Company has announced the formation of its Advisory Team, comprising industry veterans Kevin Brodwick (Thinksport/Thinksport), Guy Berechit (former J&J), and Christopher Gavigan (The Honest Company, Prima). This team brings extensive experience in CPG, entrepreneurship, and brand building to support The Nice Company's growth as it expands its retail presence and prepares to launch new products with redesigned packaging. The company, founded by Cisy Liu and Oscar Wang, aims to reimagine everyday household essentials with a focus on comfort, care, and thoughtful design.
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Revolution Medicines (NASDAQ:RVMD) is highlighted as a potential acquisition target for big pharma due to its strong late-stage RAS(ON) oncology pipeline, particularly daraxonrasib's impressive pancreatic cancer data. Merck (NYSE:MRK) is identified as the most likely acquirer, driven by the impending patent cliff for its drug Keytruda and its stated goal of diversifying its growth portfolio. Other plausible acquirers include Pfizer, Johnson & Johnson, Bristol Myers Squibb, and Roche, but Merck has the strongest motive and means.
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns
Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak Carvykti sales data. Despite these challenges, Legend Biotech recently reported strong Q2 results, exceeding revenue and earnings expectations, achieving company-wide profitability, and showing significant growth in CARVYKTI sales.
Madrigal Pharmaceuticals appoints J&J executive to board
Madrigal Pharmaceuticals (NASDAQ:MDGL) has announced the appointment of John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed is currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, overseeing R&D across various therapeutic areas. Madrigal Pharmaceuticals is focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its FDA and European Commission-approved medication, Rezdiffra.
Intuitive Surgical upgraded at Oppenheimer on robotic surgery market growth
Oppenheimer has upgraded Intuitive Surgical (ISRG) to outperform, citing the company's strong position to benefit from the growing robotic surgery market. Despite increasing competition from companies like Johnson & Johnson (JNJ), Oppenheimer believes Intuitive Surgical will maintain its market dominance. This upgrade reflects confidence in ISRG's future performance in the expanding surgical robotics sector.
Intuitive Surgical: Oppenheimer now bullish, sees competition being "crowded out"
Oppenheimer upgraded Intuitive Surgical to Outperform with a $500 price target, citing the company's effective strategy of "Crowding Out Competitors." The firm believes U.S. competition is not a significant threat due to workflow challenges for Ottava and real-estate issues for Hugo, while Intuitive's customized contracts make it financially difficult for rivals. However, international competition, particularly from Chinese platforms, poses a more substantial challenge.
Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall
Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform with a $500 price target, citing issues with competitors Johnson & Johnson's Ottava system and Medtronic's Hugo. The firm believes Intuitive's da Vinci franchise will face no credible domestic challenger in the near term and that its Per Click Model can expand into lower-acuity surgery centers. This upgrade follows similar positive revisions from UBS and Morgan Stanley in late July, despite the stock being down over 30% year-to-date.
Annex Advisory Services LLC Sells 5,431 Shares of Johnson & Johnson $JNJ
Annex Advisory Services LLC decreased its stake in Johnson & Johnson by 16%, selling 5,431 shares and retaining 28,619 shares valued at $7.27 million. This comes as Johnson & Johnson reported strong second-quarter results with revenue up 6.6% to $25.31 billion and adjusted EPS of $2.90, along with FDA authorization for its OTTAVA robotic surgery system. Analysts maintain a "Moderate Buy" rating for J&J, despite concerns over valuation, patent expirations, and ongoing talc litigation.
Diversified Management Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ
Diversified Management Inc. significantly reduced its stake in Johnson & Johnson (NYSE:JNJ) by 61.1% in the second quarter, selling 12,147 shares and leaving its holdings valued at $1.96 million. This comes as Johnson & Johnson reported stronger-than-expected Q2 earnings and raised its full-year outlook, alongside receiving FDA approval for a new robotic surgery system. Despite positive news and a "Moderate Buy" consensus rating from analysts, concerns remain regarding patent expirations, competition, and ongoing talc litigation, even with a proposed $5.5 billion settlement framework.
ACWV Dividend: 1.87% Yield, $2.36/Share — History & Dates | GuruFocus
This article provides a detailed dividend history and financial metrics for the iShares MSCI Global Min Vol Factor ETF (ACWV). It highlights ACWV's 1.87% dividend yield, $2.36 annual dividend per share, 0.46 payout ratio, and its 15-year history of paying dividends. The report also includes dividend growth rates over 1, 3, 5, and 10 years, alongside ex-dividend dates and amounts.
JNJ Keeps Climbing. Should You Climb On?
Johnson & Johnson (JNJ) has seen its stock climb significantly over the past year, outperforming the S&P 500, driven by strong performance in its Innovative Medicine business. While the company's elite business quality and key drug growth are fueling this momentum, investors face a dilemma due to the stock's high valuation and signs of strain in its MedTech division. The article questions whether pharmaceutical growth can offset MedTech's slowdown and emphasizes the importance of JNJ hitting its updated full-year operational sales growth forecast for 2026.
Pfizer (PFE) Agrees To $44 Million Class Action Settlement
Pfizer has agreed to a US$44 million class action settlement concerning its Chantix smoking cessation drug, addressing allegations of undisclosed carcinogenic nitrosamines. This settlement is considered small relative to Pfizer's substantial revenue, fitting within existing regulatory and product liability risk frameworks rather than introducing new long-term concerns. Investors are advised to monitor future financial filings for additional disclosures regarding product safety and litigation.
DIVL Dividend: 1.71% Yield, $0.44/Share — History & Dates
This article provides a comprehensive overview of the Madison Dividend Value ETF (DIVL) dividend history and yield. It details the current dividend yield of 1.68% ($0.44 per share annually), its payout ratio, and historical dividend growth rates. The article also includes a complete list of past dividend payments with ex-dividend dates and addresses frequently asked questions about DIVL's dividend performance.
Invesco's PEY ETF outperforms with a dividend-growth filter, offering higher returns and reliable income.
Invesco's High Yield Equity Dividend Achievers ETF (PEY) employs a strategy of selecting dividend-growing stocks with at least a decade of consistent dividend increases, filtering for high yield to avoid risky cuts. This approach has led to significant outperformance against the S&P 500 in 2026, delivering a 24.68% year-to-date return and a 4.11% dividend yield. The ETF focuses on stable companies like Verizon, Johnson & Johnson, and McDonald's, making it suitable for income-focused investors seeking growth and monthly payouts, though tax implications and sector concentration should be considered.
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
Scholar Rock has removed a Novo Nordisk fill-finish plant from its approval filing for a spinal muscular atrophy therapy after the FDA classified an inspection of the facility as Official Action Indicated (OAI). This decision comes despite Scholar Rock's earlier claims of "significant progress" at the plant, which Novo Nordisk acquired from Catalent in 2024. The biotech company will now proceed with a second facility that has a consistent track record, aiming to mitigate potential delays for U.S. and European approvals.
Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?
Johnson & Johnson (JNJ) is currently trading near its 52-week high, with analysts giving it a "Hold" rating due to its strong performance and pipeline balanced by valuation concerns and some declining product lines. While the company projects double-digit growth by the decade's end, the article suggests that investors might want to wait for a potential pullback or clearer catalysts before buying in, as much of the good news is already priced into the stock. Current shareholders are advised to monitor key triggers like pivotal clinical data, MedTech reacceleration, and the upcoming Enterprise Business Review.
We're lifting our price target on Cardinal Health after issuing rosy profit guidance
Cardinal Health's robust full-year earnings guidance has led to an increased price target, despite a revenue miss in its fiscal fourth quarter. The company's focus on high-margin areas like specialty pharmaceuticals and strong free cash flow generation are key drivers of its improved profitability. While some gains were attributed to tariff refunds, the underlying operational efficiency and earnings growth are highlighted as reasons to maintain a positive outlook on the stock.
The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run
The author continues to invest in Intuitive Surgical (ISRG) despite a 30.54% year-to-date decline, believing the company's "razor and razorblade" business model and its dominant position in surgical robotics make it a long-term compounder. Key factors include the growing installed base of da Vinci systems, the early stages of the dV5 supercycle with significant technological advancements, and a strong balance sheet with substantial cash and increasing free cash flow. The article highlights that ISRG faces minimal soft-tissue competition from alternatives like Medtronic's Hugo or Johnson & Johnson's Ottava, which are still in early or pre-commercial stages.
BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating
BNP Paribas has increased its price target for AbbVie (ABBV) shares to $247 from $218, while reiterating a Neutral rating on the stock. The adjustment comes as part of ongoing analyst evaluations of the pharmaceutical company. AbbVie specializes in therapeutic drug research and development across various conditions, with a significant portion of its net sales coming from the United States.
Argus Adjusts Price Target on Merck & Co. to $145 From $130, Keeps Buy Rating
Argus has raised its price target for Merck & Co. (MRK) to $145 from $130, while maintaining a Buy rating on the stock. The adjustment reflects a positive outlook for the pharmaceutical company. This news was published on August 11, 2026, at 08:57 am EDT.
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5%
Legend Biotech reported stronger-than-expected Q2 2026 results, achieving its first quarter of company-wide profitability with adjusted earnings of $0.16 per share and revenue of $387.5 million, significantly beating analyst estimates. The company's lead CAR-T therapy, CARVYKTI, saw worldwide net trade sales increase 50% year-over-year, driving a 5.03% stock rise in premarket trading. Legend Biotech also provided updates on its pipeline, including plans to file a U.S. IND for its in vivo CAR-T candidate LB2501 by the end of 2026, and expects adjusted net income profitability to continue through the second half of 2026.
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
IDEXX Laboratories has launched the Catalyst proBNP Test, a new dual-species, in-clinic test for NT-proBNP, expanding its cardiac diagnostic capabilities. This test provides rapid, laboratory-level accurate results for assessing heart disease in cats and dogs, a condition often underdiagnosed in general practice. The Catalyst proBNP Test aims to reduce reliance on multi-step referrals and improve early detection and management of cardiac conditions in companion animals.
AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB
Handelsbanken Fonder AB reduced its stake in AbbVie Inc. by 1.4% during the second quarter, selling 19,132 shares and now owning 1,362,464 shares worth $342.85 million. Despite this, AbbVie remains a "Moderate Buy" among analysts, with recent positive news including the acquisition of Apogee Therapeutics and potential new FDA indications for Botox Cosmetic. The company also reported strong Q2 earnings, beating analyst expectations, and announced a quarterly dividend of $1.73 per share.
Perkins Coie Trust Co Lowers Stock Position in Medtronic PLC $MDT
Perkins Coie Trust Co significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 98.4% in the second quarter, now holding only 639 shares. Despite this, institutional investors still own a substantial 82.06% of the company's stock. Medtronic reported strong quarterly revenue and earnings, increased its dividend, and maintains a "Moderate Buy" consensus rating from analysts, with UBS upgrading the stock due to an ongoing turnaround.
What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders
Johnson & Johnson recently reported strong Q2 2026 results, gained FDA authorization for its OTTAVA robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise, and proposed a $5.50 billion talc settlement. These strategic moves aim to reposition the company towards high-growth innovative medicines and medical technologies while addressing ongoing legal liabilities. The FDA's approval of OTTAVA is particularly significant, placing J&J in the soft tissue robotics market and aligning with its broader MedTech expansion.
Watch Johnson & Johnson’s Healthcare Conference Chat Sept. 14
Johnson & Johnson (NYSE: JNJ) announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Management will host a Fireside Chat at 11:30 a.m. Eastern Time, which will be accessible via a live audio webcast on the company's Investor Relations website. An archived replay will be available approximately 48 hours after the event.
NextCure (NXTC) plans reverse merger with Avere and $820M financings
NextCure, Inc. (NXTC) and Avere Therapeutics are planning an all-stock reverse merger, with the combined entity to operate as Avere Therapeutics, Inc. and trade on Nasdaq under "AVRX." Avere announced a new $500 million private placement, in addition to a previously disclosed $320 million concurrent private investment, bringing total pre-closing financings to $820 million, intended to fund operations into 2029. This funding will advance their lead oral IL-23 receptor antagonist, AVR-001, through multiple Phase 2b trials and towards Phase 3 in psoriasis, with potential expansion into other inflammatory diseases.
ASC GPO inks deal with J&J for cardiac electrophysiology tech
Access GPO has finalized a deal with Johnson & Johnson for cardiac electrophysiology technologies, including pulsed field and radiofrequency ablation, 3D mapping, and intracardiac imaging. This partnership aims to enhance ASCs' capabilities in cardiac care. The agreement was announced on August 10, 2026.
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Insight Molecular Diagnostics Inc. (IMDX) reported its second-quarter 2026 results, highlighting significant progress in the FDA review of its GraftAssureDx product, with marketing authorization expected. The company also noted favorable Medicare reimbursement policies and strong interest from major U.S. reference labs for in-house dd-cfDNA testing. Financially, IMDX is primarily pre-revenue from kit sales, but is strategically investing in commercial launch preparations despite a net loss of $11.3 million for the quarter.
ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?
Intuitive Surgical (ISRG) currently trades at a premium P/E ratio compared to its industry, despite a "D" Value Score, suggesting its shares are not inexpensive. The company reported strong Q2 2026 results with revenue and EPS growth, driven by increases in da Vinci and Ion procedures and improved margin outlook. While U.S. procedure growth has moderated and competition is emerging, ISRG's expanding product ecosystem, international growth, and focus on innovation support a constructive view for existing investors, leading to a Zacks Rank #3 (Hold) recommendation.
DePuy Synthes to establish center in India as J&J reportedly looks to sell the business
DePuy Synthes, a Johnson & Johnson Medtech business, plans to establish a new Global Capability Centre (GCC) in Bangalore, India, to enhance clinical innovation and operational excellence. This move comes as India is projected to be the fastest-growing regional market for orthopedic devices, reaching $3.03 billion by 2030. The establishment of the center, which will host about 500 professionals, coincides with reports that Johnson & Johnson is working to sell its DePuy Synthes Orthopaedics business, potentially valued over $20 billion.
Kimberly-Clark plans major shakeup after Kenvue deal
Kimberly-Clark is accelerating its acquisition of Kenvue, planning to consolidate systems and operations to achieve $1.9 billion in cost synergies and expand its health and wellness portfolio. The $48.7 billion deal, expected to close by the end of 2026, will create a $32 billion revenue company with major brands like Tylenol and Huggies. This integration builds on Kimberly-Clark's existing transformation efforts, including automation and AI adoption, aiming to create lasting value for shareholders.
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs
Xcellon Biologics has acquired a 40,000-square-foot GMP biologics manufacturing facility from NextCure in Beltsville, Maryland. This acquisition provides Xcellon with its first cGMP capacity, transforming it into an end-to-end CRDMO for bioconjugates and complex biologics, with GMP operations expected to commence in December 2026. The move significantly expands Xcellon's footprint and accelerates its timeline for offering integrated antibody development, bioconjugation, analytical sciences, and GMP manufacturing services.
ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?
Intuitive Surgical (ISRG) is trading at a premium P/E ratio compared to its industry, despite a "D" Value Score. While the company delivered strong second-quarter 2026 results with significant revenue and earnings growth, the premium valuation raises concerns. Management's positive forward guidance, including sustained procedure growth and improved margin outlook, supports a constructive view, suggesting existing investors might consider holding the stock.
Bristol Myers to build $2.3 billion manufacturing site in Houston
Bristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing facility in Houston, Texas, creating nearly 500 skilled jobs and approximately 2,000 construction jobs. This initiative is part of the company's $40 billion commitment to U.S. investments and aligns with a broader trend of drugmakers expanding their manufacturing capacity within the United States due to administrative pressure and incentives. The facility, expected to be operational between 2027 and 2030, will produce small-molecule medicines, biologics, and antibody-drug conjugates.
ACCESS GPO signs multiyear cardiac electrophysiology agreement with Johnson & Johnson for ambulatory surgery centers
ACCESS GPO has signed a multiyear agreement with Johnson & Johnson to provide advanced cardiac electrophysiology technologies to ambulatory surgery centers (ASCs). This collaboration aims to expand patient access to arrhythmia treatments in outpatient settings, supported by an integrated portfolio of 3D mapping, imaging, radiofrequency ablation, and pulsed field ablation technologies. The deal is expected to streamline technology adoption for physician-led ASCs and meet the growing demand for catheter ablation procedures, allowing ASCs to offer similar advanced care as hospitals but with greater efficiency.
Legend Biotech in spotlight: Earnings test Carvykti momentum
Legend Biotech is set to report its second-quarter earnings, with investors focused on the sustained growth of its CAR-T therapy, Carvykti, amidst increasing competition and a recent CEO departure. Analysts anticipate improved earnings and revenue for the quarter, but concerns linger regarding competitive threats from rival therapies and the company's leadership transition. The earnings call will also provide insights into pipeline progress and the long-term viability of Legend's valuation.
Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?
Johnson & Johnson (JNJ) has received FDA authorization for its OTTAVA robotic surgical system, marking its entry into the U.S. soft-tissue robotic surgery market. While OTTAVA features a differentiated table-integrated architecture, it faces a significant challenge from Intuitive Surgical (ISRG), which boasts a large installed base and a rapidly expanding da Vinci platform. Investors will be monitoring OTTAVA's commercial rollout and adoption rates to see if J&J can meaningfully compete in this established market.
